Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
361 Leser
Artikel bewerten:
(1)

Veritas takes its innovative prevention based genetic services portfolio to the European Society of Human Genetics (ESHG) Conference 2022 and will present results from WGS genomic screenings in 400 patients from the Clínica Universidad de Navarra

Finanznachrichten News
  • For years, the European Human Genetics Conference has been a global landmark event due to the presence of the best human genetics specialists in the world and the quality and interest of the presentations.

  • During the conference, which will take place from June 11 to 14 in Vienna, Veritas will present a summary of results from more than 400 whole genome sequencing based genetic analysis from the the Clínica Universidad de Navarra.

MADRID, June 10, 2022 /PRNewswire/ -- Veritas Intercontinental will take part in the European Society of Human Genetics (ESHG) Conference which will be held from June 11 to 14 at the Austria Center Vienna. The event will bring together companies and speakers from around the world, leaders in the world of genomics, where the latest advances in human genetics will be presented.

For years, the European Human Genetics Conference has been a global landmark event due to the presence of renowned human genetics specialists and the quality and interest of its many scientific presentations.

The ESHG Conference has two principal objectives: to provide a platform for the dissemination of the most interesting advances in the field of human genetics, and to promote the education of the next generation of human geneticists. The concurrent and educational plenary sessions, concurrent symposia, workshops and poster exhibitions complete an exciting programme.

In this context, along with specialists from the Clínica Universidad de Navarra, Veritas presents a poster which details the results of a genomic based analyses of 400 patients from the medical check-up unit at the clinic, which have found clinically relevant findings in a significant percentage of cases. "In a patient carrying a pathogenic variant in their genes that is responsible for a disease, we can also determine the probability, which is also high, of developing a specific disease. Thanks to the analysis utilizing whole genome sequencing and clinical interpretation, we can establish appropriate control and follow-up measures for each specific case, which gives us the opportunity to carry out predictive and preventive health care, anticipating as much as possible the development of the disease in order to avoid it or detect it at an early stage," details Dr Luis Izquierdo, Chief Medical Officer at Veritas, "Results like those obtained in the Medical Check-up unit at the Clínica Universidad de Navarra" -continues Dr Izquierdo-"reveal the fundamental role of genomics in the context of personalised medicine, with greater focus in preserving health than in alleviating disease."

The Scientific Programme Committee (SPC) defines the themes with the aim of updating the public in relation to the concepts, mechanisms and technologies emerging in human genetics, while also providing an extensive overview of the progress made within the different areas of this discipline.

The ESHG in Vienna provides an ideal platform to enable direct contact between scientists and exhibitors. The event, which takes place annually, addresses three large sectors: training, laboratory technology and laboratories.

Exhibitors

The exhibition area will gather more than 140 companies from this sector, a fact that demonstrates its vitality and growing interest. On its stand, X4-954, Veritas will exhibit its wide range of options which, within preventive medicine, notably include its whole genome sequencing (myGenome). It will also be displaying a complete portfolio of tests which range from risk of hereditary oncological or cardiovascular disease, to a complete range of tests oriented towards perinatal medicine, along with genetic diagnostic services and genetic counselling.

About Veritas Intercontinental

Veritas Intercontinental was founded in 2018 thanks to Dr Luis Izquierdo, Dr Vincenzo Cirigliano and Javier de Echevarría, who have amassed extensive experience in the field of genetics, diagnosis and biotechnology. Initially linked to Veritas Genetics, a company founded in 2014 by Professor George Church, one of the pioneers in preventive medicine, Veritas was established with the objective of integrating genome sequencing and its clinical interpretation into general healthcare as a tool for preventing disease, improving health and quality of life.

In March 2022, Veritas announced that it would become part of LetsGetChecked, a company with headquarters in Dublin and New York which provides global health solutions and the tools to manage health from home through direct access to diagnostic tests and virtual care.

For more information

https://www.veritasint.com

© 2022 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.